Background/Aims: The benzophenone garcinol from dried fruit rind of Garcinia indica counteracts malignancy, an effect at least in part due to stimulation of apoptosis. The proapototic effect of garcinol is attributed in part to inhibition of histone acetyltransferases and thus modification of gene expression. Moreover, garcinol triggers mitochondrial depolarisation. Erythrocytes lack gene expression and mitochondria but are nevertheless able to enter apoptosis-like suicidal death or eryptosis, which is characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Stimulators of eryptosis include oxidative stress, energy depletion and Ca2+ entry with increase of cytosolic Ca2+ activity ([Ca2+]i). The present study explored, whether and how garcinol induces eryptosis. Methods: To this end, phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca2+]i from Fluo3-fluorescence, ROS formation from DCFDA dependent fluorescence and cytosolic ATP levels utilizing a luciferin-luciferase-based assay. Results: A 24 hours exposure of human erythrocytes to garcinol (2.5 or 5 µM) significantly increased the percentage of annexin-V-binding cells. Garcinol decreased (at 1 µM and 2.5 µM) or increased (at 5 µM) forward scatter. Garcinol (5 µM) further increased Fluo3-fluorescence, increased DCFDA fluorescence, and decreased cytosolic ATP levels. The effect of garcinol on annexin-V-binding was significantly blunted, but not abolished by removal of extracellular Ca2+. Conclusions: Garcinol triggers cell shrinkage and phospholipid scrambling of the erythrocyte cell membrane, an effect in part due to stimulation of ROS formation, energy depletion and Ca2+ entry.

The benzophenone garcinol [1], a component of the dried fruit rind of Garcinia indica [1,2,3], has been shown to counteract oxidative stress [2,3,4], inflammation [2,4,5] and malignancy [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17]. Garcinol is effective against malignancy at least in part by triggering suicidal cell death or apoptosis [8,11,12,14,16,18,19,20,21,22]. On the other hand, garcinol could counteract apoptosis [23]. Cellular mechanisms involved in the effects of garcinol include inhibition of histone acetyltransferases and thus modification of gene expression [10,13,15,18,24,25,26,27], down-regulation of nuclear factor NF-κB [5,7,8,16,18,19,23], signal transducer and activator of transcription 3 (STAT3) [5,6,28], cyclin-dependent kinase 2 (CDK2) [4],p38 kinase [4], and phosphoinositide 3 kinase (PI3K)/Akt signaling [21]. Garcinol treatment leads to growth arrest and expression of DNA damage-inducible gene 153 (GADD153) [29]. Garcinol further triggers mitochondrial depolarisation [29].

Similar to apoptosis of nucleated cells, erythrocytes may enter eryptosis [30], a suicidal death characterized by cell shrinkage [31] and cell membrane scrambling with phosphatidylserine translocation to the cell surface [30]. Triggers of eryptosis include Ca2+ entry through Ca2+ permeable unselective cation channels with increase of cytosolic Ca2+ activity ([Ca2+]i). Eryptosis is further stimulated by ceramide [32], oxidative stress [30], energy depletion [30], activated caspases [30,33,34], casein kinase 1α, Janus-activated kinase JAK3, protein kinase C and p38 kinase [30]. Eryptosis is inhibited by AMP activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase, and sorafenib/sunitinib sensitive kinases [30]. Eryptosis may be stimulated by a wide variety of xenobiotics [30,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60].

The present study explored whether and how garcinol triggers eryptosis. To this end, human erythrocytes from healthy volunteers were exposed to garcinol and phosphatidylserine surface abundance, cell volume, [Ca2+]i and abundance of reactive oxygen species (ROS) determined by flow cytometry.

Erythrocytes, solutions and chemicals

Fresh Li-Heparin-anticoagulated blood samples were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). The blood was centrifuged at 120 g for 20 min at 21°C and the platelets and leukocytes-containing supernatant was disposed. Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES; pH 7.4), 5 glucose, 1 CaCl2 at 37°C for 24 h. Where indicated, erythrocytes were exposed to garcinol (Tocris bioscience, Bristol, UK) at the indicated concentrations.

Annexin-V-binding and forward scatter

After incubation under the respective experimental condition, 150 µl cell suspension was washed in Ringer solution containing 5 mM CaCl2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 20 min under protection from light. The annexin V abundance at the erythrocyte surface was subsequently determined on a FACS Calibur (BD, Heidelberg, Germany). A dot plot of forward scatter (FSC) vs. side scatter (SSC) was set to linear scale for both parameters. The threshold of forward scatter was set at the default value of “52”.

Hemolysis

For the determination of hemolysis, the samples were centrifuged (3 min at 1600 rpm, room temperature) after incubation under the respective experimental conditions and the supernatants were harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration of the supernatant was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.

Intracellular Ca2+

After incubation, erythrocytes were washed in Ringer solution and then loaded with Fluo-3/AM (Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl2 and 5 µM Fluo-3/AM. The cells were incubated at 37°C for 30 min and washed once in Ringer solution containing 5 mM CaCl2. The Fluo-3/AM-loaded erythrocytes were resuspended in 200 µl Ringer. Then, Ca2+-dependent fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur.

Reactive oxidant species (ROS)

Oxidative stress was determined utilizing 2', 7'-dichlorodihydrofluorescein diacetate (DCFDA). After incubation, a 100 µl suspension of erythrocytes was washed in Ringer solution and then stained with DCFDA (Sigma, Schnelldorf, Germany) in PBS containing DCFDA at a final concentration of 10 µM. Erythrocytes were incubated at 37°C for 30 min in the dark and then washed in PBS. The DCFDA-loaded erythrocytes were resuspended in 200 µl Ringer solution, and ROS-dependent fluorescence intensity was measured at an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD).

Intracellular ATP concentration

For the determination of intracellular erythrocyte ATP, 80 µl of erythrocyte pellets were incubated for 24 h at 37°C in Ringer solution (final hematocrit 4.7%). All subsequent manipulations were performed at 4°C to avoid ATP degradation. Cells were lysed in distilled water, and proteins were precipitated by addition of HClO4 (6%). After centrifugation, an aliquot of the supernatant (400 µl) was adjusted to pH 7.7 by addition of saturated KHCO3 solution. After dilution of the supernatant, the ATP concentrations of the aliquots were determined utilizing the luciferin-luciferase assay kit (Roche Diagnostics) on a luminometer (Berthold Biolumat LB9500, Bad Wildbad, Germany) according to the manufacturer's protocol. ATP concentrations are expressed in mmol/l cytosol of erythrocytes.

Statistics

Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA with Tukey's test as post-test and t test as appropriate. n denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.

The present study tested, whether garcinol modifies eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the cell surface. In order to uncover cell membrane scrambling, phosphatidylserine at the erythrocyte surface was visualized with annexin-V-binding, which was determined by flow cytometry. Prior to measurement, erythrocytes were incubated for 24 hours in Ringer solution without or with garcinol (1 - 5 µM). As shown in Fig. 1, a 24 hours exposure to garcinol increased the percentage of phosphatidylserine exposing erythrocytes, an effect reaching statistical significance at 2.5 µM garcinol. For comparison, hemolysis was quantified from the hemoglobin concentration in the supernatant. As a result, the percentage of hemolytic erythrocytes was significantly higher following exposure to 5 µM garcinol than in the absence of garcinol (Fig. 1). However, the percentage of hemolytic erythrocytes remained lower than the percentage of annexin-V-binding erythrocytes (Fig. 1).

Fig. 1

Effect of garcinol on phosphatidylserine exposure. (A) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of 5 µM garcinol. (B) Arithmetic means ± SEM (n = 12) of erythrocyte annexin-V-binding (black bars) following incubation for 24 hours to Ringer solution without or with presence of garcinol (1 - 5 µM). For comparison, arithmetic means ± SEM (n = 12) of hemolysis are shown (grey bars). * (p<0.05), *** (p<0.001), ### (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Fig. 1

Effect of garcinol on phosphatidylserine exposure. (A) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of 5 µM garcinol. (B) Arithmetic means ± SEM (n = 12) of erythrocyte annexin-V-binding (black bars) following incubation for 24 hours to Ringer solution without or with presence of garcinol (1 - 5 µM). For comparison, arithmetic means ± SEM (n = 12) of hemolysis are shown (grey bars). * (p<0.05), *** (p<0.001), ### (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Close modal

Erythrocyte volume was estimated from forward scatter, which was determined utilizing flow cytometry. As illustrated in Fig. 2, a 24 hours incubation in Ringer solution with 1 and 2.5 µM garcinol was followed by a significantly lower erythrocyte forward scatter than a 24 hours incubation in Ringer solution without garcinol. In contrast, a 24 hours incubation in Ringer solution with 5 µM garcinol was followed by a significantly higher erythrocyte forward scatter than a 24 hours incubation in Ringer solution without garcinol. Thus, 1 µM and 2.5 µM garcinol shrank but 5 µM garcinol swelled erythrocytes.

Fig. 2

Effect of garcinol on erythrocyte forward scatter. (A) Original histogram of forward scatter of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of 2.5 µM garcinol. (B) Arithmetic means ± SEM (n = 12) of the erythrocyte forward scatter (FSC) following incubation for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1 - 5 µM). ** (p<0.01), *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Fig. 2

Effect of garcinol on erythrocyte forward scatter. (A) Original histogram of forward scatter of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of 2.5 µM garcinol. (B) Arithmetic means ± SEM (n = 12) of the erythrocyte forward scatter (FSC) following incubation for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1 - 5 µM). ** (p<0.01), *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Close modal

In order to quantify cytosolic Ca2+ activity ([Ca2+]i), Fluo3 fluorescence was measured. As illustrated in Fig. 3, a 24 hours exposure to garcinol increased the Fluo3 fluorescence, an effect reaching statistical significance at 5 µM garcinol.

Fig. 3

Effect of garcinol on erythrocyte Ca2+ activity. (A) Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM). (B) Arithmetic means ± SEM (n = 12) of the Fluo3 fluorescence (arbitrary units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1 - 5 µM). *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Fig. 3

Effect of garcinol on erythrocyte Ca2+ activity. (A) Original histogram of Fluo3 fluorescence in erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM). (B) Arithmetic means ± SEM (n = 12) of the Fluo3 fluorescence (arbitrary units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1 - 5 µM). *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Close modal

In order to test whether garcinol -induced translocation of phosphatidylserine or erythrocyte shrinkage required entry of extracellular Ca2+, erythrocytes were incubated for 24 hours in the absence or presence of 5 µM garcinol in the presence or nominal absence of extracellular Ca2+. As shown in Fig. 4, removal of extracellular Ca2+ slightly, but significantly blunted the effect of garcinol on annexin-V-binding. However, garcinol significantly increased the percentage of annexin-V-binding erythrocytes even in the absence extracellular Ca2+. Garcinol-induced cell membrane scrambling was thus partially but not fully due to entry of extracellular Ca2+.

Fig. 4

Ca2+ sensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the presence (A) and absence (B) of extracellular Ca2+. (C) Arithmetic means ± SEM (n = 12) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. *** (P<0.001) indicates significant difference from the absence of garcinol, ##(p<0.01) indicate significant difference from the presence of Ca2+ (ANOVA).

Fig. 4

Ca2+ sensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the presence (A) and absence (B) of extracellular Ca2+. (C) Arithmetic means ± SEM (n = 12) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the presence (left bars, +Ca2+) and absence (right bars, -Ca2+) of Ca2+. *** (P<0.001) indicates significant difference from the absence of garcinol, ##(p<0.01) indicate significant difference from the presence of Ca2+ (ANOVA).

Close modal

Removal of extracellular Ca2+ did not significantly blunt the effect of 5 µM garcinol on forward scatter. In the absence of garcinol the forward scatter was virtually identical in the presence (437 ± 8, n = 12) and in the absence (437 ± 5, n = 12) of extracellular Ca2+ and incubation with 5 µM garcinol increased the forward scatter to similar values in the presence (473 ± 6, n = 12) and in the absence (480 ± 5, n = 12) of extracellular Ca2+.

Additional experiments explored whether the effect of garcinol was modified by the NF-κB inhibitor Bay 11-7082. As a result, Bay 11-7082 (20 µM) tended to increase annexin-V-binding of erythrocytes in the presence and absence of 5 µM garcinol, an effect, however, not reaching statistical significance (Fig. 5).

Fig. 5

Bay 11-7082 sensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the absence (A) and presence (B) of Bay 11-7082 (20 µM). (C) Arithmetic means ± SEM (n = 8) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the absence (left bars, -BAY) and presence (right bars, +BAY) of Bay 11-7082 (20 µM). *** (P<0.001) indicates significant difference from the absence of garcinol (ANOVA).

Fig. 5

Bay 11-7082 sensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the absence (A) and presence (B) of Bay 11-7082 (20 µM). (C) Arithmetic means ± SEM (n = 8) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the absence (left bars, -BAY) and presence (right bars, +BAY) of Bay 11-7082 (20 µM). *** (P<0.001) indicates significant difference from the absence of garcinol (ANOVA).

Close modal

In order to quantify oxidative stress, reactive oxygen species (ROS) was determined with 2′, 7′-dichlorodihydrofluorescein diacetate (DCFDA). As shown in Fig. 6, a 24 hours exposure to garcinol (1 - 5 µM) significantly increased the DCFDA fluorescence. Accordingly, garcinol induced oxidative stress.

Fig. 6

Effect of garcinol on erythrocyte ROS formation. (A) Original histogram of DCFDA fluorescence in erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM). (B) Arithmetic means ± SEM (n = 12) of the DCFDA fluorescence (arbitrary units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1- 5 µM). *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Fig. 6

Effect of garcinol on erythrocyte ROS formation. (A) Original histogram of DCFDA fluorescence in erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM). (B) Arithmetic means ± SEM (n = 12) of the DCFDA fluorescence (arbitrary units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (1- 5 µM). *** (p<0.001) indicate significant difference from the absence of garcinol (ANOVA).

Close modal

Additional experiments explored whether the effect of garcinol was modified by the antioxidant N-acetylcysteine (3 mM). As a result, N-acetylcysteine did not significantly modify the effect of 5 µM garcinol on annexin-V-binding of erythrocytes (Fig. 7).

Fig. 7

N-Acetylcysteine insensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the absence (A) and presence (B) of N-acetylcysteine (3 mM). (C) Arithmetic means ± SEM (n = 8) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the absence (left bars, -N-acetylcysteine) and presence (right bars, +N-acetylcysteine) of N-acetylcysteine (3 mM). *** (P<0.001) indicates significant difference from the absence of garcinol (ANOVA).

Fig. 7

N-Acetylcysteine insensitivity of garcinol-induced phosphatidylserine exposure. (A, B) Original histogram of annexin-V-binding of erythrocytes following exposure for 24 hours to Ringer solution without (grey area) and with (black line) presence of garcinol (5 µM) in the absence (A) and presence (B) of N-acetylcysteine (3 mM). (C) Arithmetic means ± SEM (n = 8) of annexin-V-binding of erythrocytes after a 24 hours treatment with Ringer solution without (white bars) or with (black bars) garcinol (5 µM) in the absence (left bars, -N-acetylcysteine) and presence (right bars, +N-acetylcysteine) of N-acetylcysteine (3 mM). *** (P<0.001) indicates significant difference from the absence of garcinol (ANOVA).

Close modal

In order to explore whether garcinol triggers energy depletion, ATP levels were determined utilizing a luciferin-luciferase assay. As illustrated in Fig. 8, a 24 hours exposure to garcinol decreased the cytosolic ATP levels, an effect reaching statistical significance at 5 µM garcinol concentration.

Fig. 8

Effect of garcinol on erythrocyte ATP concentration. Arithmetic means ± SEM (n = 5) of the cytosolic ATP concentrations (arb. units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (5 µM). * (p<0.05) indicate significant difference from the absence of garcinol (t-test).

Fig. 8

Effect of garcinol on erythrocyte ATP concentration. Arithmetic means ± SEM (n = 5) of the cytosolic ATP concentrations (arb. units) in erythrocytes exposed for 24 hours to Ringer solution without (white bar) or with (black bars) garcinol (5 µM). * (p<0.05) indicate significant difference from the absence of garcinol (t-test).

Close modal

The present study reveals that exposure of human erythrocytes to garcinol is followed by stimulation of cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Moreover, lower concentrations of garcinol (1 and 2.5 µM) trigger cell shrinkage, the second hallmark of eryptosis, the suicidal erythrocyte death. The concentrations required for the effect are lower than those required to counteract growth of tumor cells [20]. In theory, lower garcinol concentrations may be required for triggering of eryptosis in clinical conditions associated with enhanced eryptosis susceptibility of the erythrocytes, such as dehydration [48], hyperphosphatemia [58] chronic kidney disease (CKD) [40,61,62,63], hemolytic-uremic syndrome [64], diabetes [65], hepatic failure [66], malignancy [30], sepsis [67], Sickle-cell disease [30], beta-thalassemia [30], Hb-C and G6PD-deficiency [30], as well as Wilsons disease [68]. In those disorders lower garcinol concentrations may be sufficient to trigger eryptosis.

The effect of garcinol on cell membrane scrambling was in small part due to increase of cytosolic Ca2+ activity ([Ca2+]i), which is known to trigger cell membrane scrambling by activating an illdefined scramblase [30]. Accordingly, removal of extracellular Ca2+ significantly blunted cell membrane scrambling. Ca2+ entered presumably through Ca2+ permeable cation channels, which are known to be activated by oxidative stress [30]. DCFDA fluorescence indeed revealed that high concentrations of garcinol increased the abundance of reactive oxidant species.

An increase of [Ca2+]i could further trigger erythrocyte shrinkage by activation of Ca2+ sensitive K+ channels with subsequent cell shrinkage due to K+ exit, cell membrane hyperpolarization, Cl- exit and thus cellular loss of KCl with water [31]. However, higher concentrations of garcinol are required to appreciably increase [Ca2+]i and higher concentrations of garcinol increase rather than decrease erythrocyte volume. The increase of cell volume may result from the observed decline of ATP levels, which should compromise the function of the Na+/K+ ATPase with subsequent increase of cytosolic Na+, as well as decline of cytosolic K+ with subsequent depolarization and gain of Cl- with osmotically obliged water [69].

The most important functional significance of eryptosis is removal of defective erythrocytes prior to hemolysis [30]. Hemolysis triggers release of hemoglobin, which is filtered in renal glomerula with subsequent precipitation in the acidic lumen of renal tubules and thus occlusion of nephrons [70]. Eryptosis further fosters the removal of erythrocytes infected with the malaria pathogen Plasmodium.Plasmodia induce oxidative stress with subsequent activation of Ca2+-permeable erythrocyte cation channels [30,71]. Several genetic erythrocyte disorders, such as sickle-cell trait, beta-thalassemia-trait, Hb-C and G6PD-deficiency enhance the susceptibility to triggers of eryposis and thus accelerate the removal of infected erythrocytes. As a result, the disorders blunt parasitemia and thus protect against a severe course of malaria [30,72,73,74]. Eryptosis is further fostered and thus increase of parasitemia slowed by iron deficiency [75] as well as treatment with lead [75], chlorpromazine [76] or NO synthase inhibitors [76]. In theory, garcinol may similarly foster eryptosis of plasmodium infected erythrocytes.

On the other hand, eryptosis may lead to anemia as soon as the loss of erythrocytes is not matched by a similar increase of erythrocyte formation [30]. Moreover, phosphatdylserine exposing erythrocytes may adhere to the vascular wall [77] and stimulate clotting as well as thrombosis [78,79,80]. Accordingly, excessive eryptosis may interfere with microcirculation [32,78,81,82,83,84].

Garcinol triggers cell membrane scrambling and cell shrinkage. At higher concentrations, garcinol leads to cell swelling, energy depletion, oxidative stress and increase of cytosolic Ca2+ activity.

The authors acknowledge the meticulous preparation of the manuscript by Tanja Loch. The study was supported by the Deutsche Forschungsgemeinschaft and Open Access Publishing Fund of Tuebingen University.

The authors state that they have nothing to disclose.

1.
Semwal RB, Semwal DK, Vermaak I, Viljoen A: A comprehensive scientific overview of Garcinia cambogia. Fitoterapia 2015;102:134-148.
2.
Liu C, Ho PC, Wong FC, Sethi G, Wang LZ, Goh BC: Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects. Cancer Lett 2015;362:8-14.
3.
Padhye S, Ahmad A, Oswal N, Sarkar FH: Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J Hematol Oncol 2009;2:38.
4.
Yu SY, Liao CH, Chien MH, Tsai TY, Lin JK, Weng MS: Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J Agric Food Chem 2014;62:2085-2095.
5.
Li F, Shanmugam MK, Chen L, Chatterjee S, Basha J, Kumar AP, Kundu TK, Sethi G: Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev Res (Phila) 2013;6:843-854.
6.
Ahmad A, Sarkar SH, Aboukameel A, Ali S, Biersack B, Seibt S, Li Y, Bao B, Kong D, Banerjee S, Schobert R, Padhye SB, Sarkar FH: Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 2012;33:2450-2456.
7.
Ahmad A, Sarkar SH, Bitar B, Ali S, Aboukameel A, Sethi S, Li Y, Bao B, Kong D, Banerjee S, Padhye SB, Sarkar FH: Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther 2012;11:2193-2201.
8.
Ahmad A, Wang Z, Wojewoda C, Ali R, Kong D, Maitah MY, Banerjee S, Bao B, Padhye S, Sarkar FH: Garcinol-induced apoptosis in prostate and pancreatic cancer cells is mediated by NF- kappaB signaling. Front Biosci (Elite Ed) 2011;3:1483-1492.
9.
Gao Y, Tollefsbol TO: Impact of Epigenetic Dietary Components on Cancer through Histone Modifications. Curr Med Chem 2015;22:2051-2064.
10.
Gerhauser C: Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr Chem 2013;329:73-132.
11.
Han CM, Zhou XY, Cao J, Zhang XY, Chen X: 13,14-Dihydroxy groups are critical for the anti-cancer effects of garcinol. Bioorg Chem 2015;60:123-129.
12.
Matsumoto K, Akao Y, Kobayashi E, Ito T, Ohguchi K, Tanaka T, Iinuma M, Nozawa Y: Cytotoxic benzophenone derivatives from Garcinia species display a strong apoptosis-inducing effect against human leukemia cell lines. Biol Pharm Bull 2003;26:569-571.
13.
Oike T, Ogiwara H, Torikai K, Nakano T, Yokota J, Kohno T: Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. Int J Radiat Oncol Biol Phys 2012;84:815-821.
14.
Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK: Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J Agric Food Chem 2001;49:1464-1474.
15.
Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S: Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol Nutr Food Res 2013;57:235-248.
16.
Parasramka MA, Gupta SV: Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. Nutr Cancer 2011;63:456-465.
17.
Parasramka MA, Gupta SV: Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. J Oncol 2012;2012:709739.
18.
Ye X, Yuan L, Zhang L, Zhao J, Zhang CM, Deng HY: Garcinol, an acetyltransferase inhibitor, suppresses proliferation of breast cancer cell line MCF-7 promoted by 17beta-estradiol. Asian Pac J Cancer Prev 2014;15:5001-5007.
19.
Ahmad A, Wang Z, Ali R, Maitah MY, Kong D, Banerjee S, Padhye S, Sarkar FH: Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J Cell Biochem 2010;109:1134-1141.
20.
Hong J, Kwon SJ, Sang S, Ju J, Zhou JN, Ho CT, Huang MT, Yang CS: Effects of garcinol and its derivatives on intestinal cell growth: Inhibitory effects and autoxidation-dependent growth-stimulatory effects. Free Radic Biol Med 2007;42:1211-1221.
21.
Liao CH, Sang S, Ho CT, Lin JK: Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells. J Cell Biochem 2005;96:155-169.
22.
Prasad S, Ravindran J, Sung B, Pandey MK, Aggarwal BB: Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol Cancer Ther 2010;9:856-868.
23.
Jing Y, Ai Q, Lin L, Dai J, Jia M, Zhou D, Che Q, Wan J, Jiang R, Zhang L: Protective effects of garcinol in mice with lipopolysaccharide/D-galactosamine-induced apoptotic liver injury. Int Immunopharmacol 2014;19:373-380.
24.
Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK: Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004;279:33716-33726.
25.
Huang J, Plass C, Gerhauser C: Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011;12:1925-1956.
26.
Kaur J, Tikoo K: p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles. Biochim Biophys Acta 2013;1833:1028-1040.
27.
Oike T, Ogiwara H, Amornwichet N, Nakano T, Kohno T: Chromatin-regulating proteins as targets for cancer therapy. J Radiat Res 2014;55:613-628.
28.
Sethi G, Chatterjee S, Rajendran P, Li F, Shanmugam MK, Wong KF, Kumar AP, Senapati P, Behera AK, Hui KM, Basha J, Natesh N, Luk JM, Kundu TK: Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol Cancer 2014;13:66.
29.
Cheng AC, Tsai ML, Liu CM, Lee MF, Nagabhushanam K, Ho CT, Pan MH: Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis. Food Funct 2010;1:301-307.
30.
Lang F, Qadri SM: Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif 2012;33:125-130.
31.
Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM: Role of Ca2+-activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560.
32.
Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F: Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012;303:C991-999.
33.
Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012;6:847-856.
34.
Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013;50:489-495.
35.
Jilani K, Lang F: Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane. Toxins (Basel) 2013;5:703-716.
36.
Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori DC: Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013;65:145-157.
37.
Zappulla D: Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr 2008;3:30-34.
38.
Lupescu A, Jilani K, Zbidah M, Lang F: Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:291-299.
39.
Abed M, Zoubi KA, Theurer M, Lang F: Effect of dermaseptin on erythrocytes. Basic Clin Pharmacol Toxicol 2013;113:347-352.
40.
Ahmed MS, Langer H, Abed M, Voelkl J, Lang F: The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013;37:158-167.
41.
Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M, Koberle M, Lang E, Dreischer P, Biedermann T, Duszenko M, Lang F, Bosman GJ, Wieder T: Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013;32:801-813.
42.
Alzoubi K, Honisch S, Abed M, Lang F: Triggering of Suicidal Erythrocyte Death by Penta-O-galloyl-beta-d-glucose. Toxins (Basel) 2014;6:54-65.
43.
Jilani K, Enkel S, Bissinger R, Almilaji A, Abed M, Lang F: Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013;5:1230-1243.
44.
Lupescu A, Bissinger R, Jilani K, Lang F: Triggering of suicidal erythrocyte death by celecoxib. Toxins (Basel) 2013;5:1543-1554.
45.
Arnold M, Lang E, Modicano P, Bissinger R, Faggio C, Abed M, Lang F: Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014;114:421-426.
46.
Oswald G, Alzoubi K, Abed M, Lang F: Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014;114:311-317.
47.
Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F: Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014;33:670-680.
48.
Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F: Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013;37:567-578.
49.
Alzoubi K, Calabròa S, Bissinger R, Abed M, Faggio C, Lang F: Stimulation of Suicidal Erythrocyte Death by Artesunate. Cell Physiol Biochem 2014;34:2232-2244.
50.
Arnold M, Bissinger R, Lang F: Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014;34:1756-1767.
51.
Bissinger R, Fischer S, Jilani K, Lang F: Stimulation of Erythrocyte Death by Phloretin. Cell Physiol Biochem 2014;34:2256-2265.
52.
Bissinger R, Lupescu A, Zelenak C, Jilani K, Lang F: Stimulation of eryptosis by cryptotanshinone. Cell Physiol Biochem 2014;34:432-442.
53.
Bissinger R, Modicano P, Frauenfeld L, Lang E, Jacobi J, Faggio C, Lang F: Estramustine-induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:1426-1436.
54.
Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F: Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014;33:1516-1526.
55.
Lupescu A, Bissinger R, Warsi J, Jilani K, Lang F: Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem 2014;33:1838-1848.
56.
Malik A, Bissinger R, Calabro S, Faggio C, Jilani K, Lang F: Aristolochic Acid Induced Suicidal Erythrocyte Death. Kidney Blood Press Res 2014;39:408-419.
57.
Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA: Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014;34:1075-1089.
58.
Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F: Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013;38:42-51.
59.
Zhang R, Xiang Y, Ran Q, Deng X, Xiao Y, Xiang L, Li Z: Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem 2014;34:1780-1791.
60.
Faggio C, Alzoubi K, Calabro S, Lang F: Stimulation of suicidal erythrocyte death by PRIMA-1. Cell Physiol Biochem 2015;35:529-540.
61.
Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F: Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014;92:871-879.
62.
Polak-Jonkisz D, Purzyc L: Ca(2+) influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012;34:209-210; author reply 210.
63.
Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
64.
Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006;84:378-388.
65.
Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232.
66.
Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA: Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015;61:275-284.
67.
Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007;85:273-281.
68.
Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
69.
Lang F, Busch GL, Gulbins E: Physiology of cell survival and cell death: implications for organ conservation. Nephrol Dial Transplant 1995;10:1551-1555.
70.
Harrison HE, Bunting H, Ordway NK, Albrink WS: The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947;86:339-356.
71.
Kirk K: Membrane transport in the malaria-infected erythrocyte. Physiol Rev 2001;81:495-537.
72.
Ayi K, Giribaldi G, Skorokhod A, Schwarzer E, Prendergast PT, Arese P: 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother 2002;46:3180-3184.
73.
Ayi K, Turrini F, Piga A, Arese P: Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-thalassemia trait. Blood 2004;104:3364-3371.
74.
Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P: Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998;92:2527-2534.
75.
Koka S, Huber SM, Boini KM, Lang C, Foller M, Lang F: Lead decreases parasitemia and enhances survival of Plasmodium berghei-infected mice. Biochem Biophys Res Commun 2007;363:484-489.
76.
Koka S, Lang C, Niemoeller OM, Boini KM, Nicolay JP, Huber SM, Lang F: Influence of NO synthase inhibitor L-NAME on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2008;21:481-488.
77.
Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012;302:C644-C651.
78.
Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
79.
Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
80.
Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988.
81.
Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
82.
Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
83.
Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
84.
Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996;88:1873-1880.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.